Comment on: Beneficial effects of nintedanib on cardiomyopathy in patients with systemic sclerosis: a pilot study: reply

Rheumatology (Oxford). 2023 Sep 1;62(9):e278-e279. doi: 10.1093/rheumatology/kead037.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Cardiomyopathies* / drug therapy
  • Cardiomyopathies* / etiology
  • Humans
  • Lung Diseases, Interstitial*
  • Pilot Projects
  • Scleroderma, Systemic* / complications
  • Scleroderma, Systemic* / drug therapy

Substances

  • nintedanib